Lysosomal Storage Disorder currently exhibits a strong pipeline with 74 drug candidates.
The study analyzed that the lysosomal storage disorder therapeutics pipeline comprises approximately 74 drug candidates in different stages of development.
According to the research findings, most of the drug candidates for lysosomal storage disorder pipeline are being developed to be administered by intravenous route.
Browse Report Description at: www.psmarketresearch.com/market-an…pipeline-analysis
Amicus Therapeutics, Inc. is using chaperone advanced replacement therapy (CHART) technology platform for the development of their drug candidates for the treatment of Fabry disease, a type of lysosomal storage disorder.
This proposed CHART mechanism may allow for enhanced tissue uptake, greater lysosomal activity, more reduction of storage material, and lower immunogenicity compared to ERT alone.
The research also found that various companies use natural sources for the development of lysosomal storage disorder therapeutics pipeline. Protalix BioTherapeutics, Inc. is developing their drug candidates, obtained from a natural source, for the treatment of Fabry disease.
Explore Report Sample at: www.psmarketresearch.com/market-an…sis/report-sample
Some of the other key players developing drugs for the treatment of lysosome storage disorder include GlaxoSmithKline plc, Sanofi Genzyme, Amicus Therapeutics, Inc. and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information:Make an Inquiry about this report HERE!